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Abstract
Background: Chronic hepatitis C virus (HCV) infection of the liver with
either genotype 1 or genotype 3 gives rise to distinct pathologies, and the two
viral genotypes respond differently to antiviral therapy. Methods: To under-
stand these clinical differences, we compared gene transcription profiles in
liver biopsies from patients infected with either gt1 or gt3, and uninfected
controls. Results: Gt1-infected biopsies displayed elevated levels of tran-
scripts regulated by type I and type III interferons (IFN), including genes that
predict response to IFN-a therapy. In contrast, genes controlled by IFN-c
were induced in gt3-infected biopsies. Moreover, IFN-c levels were higher in
gt3-infected biopsies. Analysis of hepatocyte-derived cell lines confirmed that
the genes upregulated in gt3 infection were preferentially induced by IFN-c.
The transcriptional profile of gt3 infection was unaffected by IFNL4 poly-
morphisms, providing a rationale for the reduced predictive power of IFNL
genotyping in gt3-infected patients. Conclusions: The interactions between
HCV genotypes 1 and 3 and hepatocytes are distinct. These unique interac-
tions provide avenues to explore the biological mechanisms that drive viral
genotype-specific differences in disease progression and treatment response.
A greater understanding of the distinct host–pathogen interactions of the dif-
ferent HCV genotypes is required to facilitate optimal management of HCV
infection.
Hepatitis C virus (HCV) is a highly diverse human
pathogen, which is classified into seven distinct geno-
types that vary by >30% at the nucleotide sequence level
(1). The virus establishes a chronic infection within liver
hepatocytes and is one of the leading causes of liver
disease worldwide (2). The development of novel direct-
acting antivirals (DAAs) with higher efficacy than inter-
feron (IFN) treatment (3, 4), and the first prophylactic
vaccines moving into human trials (5), raises the possi-
bility of combating HCV infection on a global scale.
However, presently licensed DAAs act on a limited
range of viral genotypes and the vaccines under develop-
ment target only genotype (gt)1 viral antigens. While
gt1 is prevalent worldwide (46.2% of HCV cases), over
half of all infections are caused by other genotypes (6).
Among these other HCV genotypes, gt3 is the most pre-
valent (accounting for 54.3 million cases, 30.1%) (6).
Achieving HCV eradication requires a better under-
standing of the host–pathogen interactions that influ-
ence the natural history of each viral genotype.
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Viral genotype is an important clinical indicator in the
management of HCV infection, affecting both disease
progression and treatment options. Gt3 infection is asso-
ciated with decreased peripheral cholesterol levels and an
increased prevalence of liver steatosis, which resolve upon
successful viral clearance (7). There is also evidence that
gt3 infection is independently associated with faster liver
fibrosis progression (8). From the perspective of antiviral
therapy, gt1-infected patients show a reduced response to
interferon-based regimens (40–50% sustained virological
response [SVR] for gt1 compared to 70–80% for gt3) (9).
Conversely, phase 3 trials of pan-genotypic DAAs indicate
gt3-infected patients are more difficult to treat with IFN-
free therapies (3).
Microarray analysis of hepatic gene expression has
yielded valuable information on host–pathogen interac-
tions during chronic HCV infection. From initial studies
in chimpanzees, persistently infected animals displayed
elevated transcription of genes including the following:
(i) antiviral interferon-stimulated genes (ISGs), (ii)
modulators of immune cell activity and (iii) regulators
of lipid metabolism (10, 11). The same approach for
analysis of human liver biopsies has identified similari-
ties in the patterns of gene expression during chronic
infection (12–15). These human and chimpanzee studies
have largely focused on gt1 infection with limited data
analysis on other viral genotypes, including gt3.
In this report, we set out to explore distinct host
responses induced by different HCV genotypes. We
hypothesise that the observed clinical features of gt1 and
gt3 infection are related to fundamental differences in the
nature of the virus–host interactions within liver cells. To
explore this hypothesis, we have analysed the transcrip-
tional changes in infected liver tissue using high-through-
put RNA sequencing (RNA-Seq). This technology offers a
broader dynamic range than microarray analysis and
enables analysis of novel unannotated RNA transcripts.
Our study aimed to create a transcriptional profile of gt1
and gt3 infection, as a platform to understand factors
influencing the genotype-specific progression of liver dis-
ease and the response to antiviral therapy.
Materials and methods
Clinical samples
Clinical samples were used with informed consent,
conforming to the ethical guidelines of the 1975
Declaration of Helsinki. Study protocols were
approved by the West of Scotland Research Ethics
Committee and the Tayside Tissue Bank Access
Committee. Liver needle biopsies from patients with
chronic HCV infection (gt1, n = 9; gt3, n = 9), car-
ried out as part of routine clinical care, were
divided, with half fixed for routine histological
examination and the remaining half snap-frozen in
liquid nitrogen. Seven of the HCV-infected individu-
als had previously failed non-pegylated interferon
therapy (4 gt1 and 3 gt3; Table 1), but none were
receiving interferon therapy at the time of liver
biopsy.
As a control group, RNA was extracted from
uninfected liver biopsy and resection samples
(n = 6). These included liver samples from patients
with conditions that are associated with hepatic dis-
ease (one each with genetic haemochromatosis, non-
alcoholic steatohepatitis and psoriasis) as well as
three normal samples obtained during liver resection
for metastatic colorectal adenocarcinoma. Clinical
data are detailed in Table 1. Q-PCR analysis of con-
served sequences in the 50 untranslated region of the
viral genome (16) confirmed that only liver biopsies
from infected patients had detectable HCV RNA, and
no difference in intrahepatic viral RNA levels was
found between either gt1- or gt3-infected patients
(data not shown).
Table 1. Clinical data for liver biopsies
Genotype 1 Genotype 3 Control
n 9 9 6
Male:Female 5:4 6:3 2:1*
Previous Treatment
Failure (Y:N)
4:5 3:6 n/a
rs368234815 Genotype
(TT/TT:TT/DG:DG/DG)†
2:5:1 6:3:0 3:2:1
Ishak Inflammation
Score (1-18)
3 (2-5) 4 (2-7) n/a
Ishak Fibrosis
Score (0-6)
0 (0-3) 0 (0-6) n/a
METAVIR Fibrosis
Score (0-4)
0 (0-2) 0 (0-4) 0.5
(0-1)
n/a, not applicable.
All values are given as the median with the range in brackets.
*Gender was unavailable for 3 anonymised control samples.
†rs368234815 genotype was unavailable for one gt1-infected patient.
Key Points
 Transcriptional profiling of liver tissue from hepa-
titis C virus-infected individuals can identify distinct
viral genotype-specific host–pathogen interactions.
 Genotype 1 infection is associated with an elevated
type I IFN-like response and is influenced by host
IFNL4 genotype.
 Genotype 3 infection is associated with transcrip-
tion of genes involved in cell-mediated immune
responses and IFN-c signalling, independent of host
IFNL4 genotype.
 Understanding the influence of viral genotype on
hepatitis C disease progression will facilitate the opti-
mal clinical management of different hepatitis C virus
genotypes, the development genotype-specific predic-
tors of therapy and the efficient utilisation of antiviral
therapeutics.
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RNA extraction
Snap-frozen liver biopsies were homogenised in 3 ml
buffer RLT (Qiagen, Manchester, UK), supplemented
with 30 ll b-mercaptoethanol, using a hand-held
power homogenizer (Polytron; Kinematica AG,
Lucerne, Switzerland), and total RNA was extracted
using RNeasy Minicolumns with on-column DNase
digestion (Qiagen). RNA quality and quantity were
assessed on a 2200 TapeStation (Agilent Technologies,
Santa Clara, CA, USA).
Illumina RNA-Seq
Samples were prepared with the Illumina TruSeq RNA
sample preparation kit (Illumina, San Diego, CA, USA)
and sequenced on an Illumina Genome Analyzer IIx
(Glasgow Polyomics, University of Glasgow, Glasgow,
UK). Raw FASTQ sequencing files (73 base reads) were
quality-filtered for low-quality bases and adaptor
sequences with Trim Galore! v0.2.4 (http://www.bioin
formatics.bbsrc.ac.uk/projects/trim_galore/). The RNA-
Seq analysis was performed using the Tuxedo protocol
(17), with full details provided in the supplementary
methods. Differential gene expression was considered
significant when the observed fold change of reads
(ΔFPKM(log2)) was ≥1.0 and FDR/q-value <0.05
between comparisons. Pathway analysis was carried out
using IPA (Ingenuity Systems, Redwood City, CA,
USA).
Quantitative real-time PCR (Q-PCR) and genotyping
Total RNA was reverse-transcribed with the Super-
Script VILOTM Kit (Life Technologies, Paisley, UK),
and gene expression was measured by quantitative
real-time PCR (Q-PCR) using TaqMan assays (Life
Technologies; Table S1). Statistical significance was cal-
culated using the Kruskal–Wallis test in GraphPad
Prism 5 (GraphPad Software, La Jolla, CA, USA). Geno-
typing of IFNL4 rs368234815 was performed on cDNA
using the assay described previously (18) with Type-it
Fast SNP Probe PCR Master Mix (Qiagen).
Microarray analysis of IFN-a- and IFN-c-stimulated
hepatocyte-derived cell lines
Human hepatocyte-derived cells (HuH-7 and HepaRG)
were mock-treated or incubated with 100 IU of IFN-a
(Merck, Kenilworth, NJ, USA) or IFN-c (Roche, Basel,
Switzerland) for 24 h (n = 2). Total cellular RNA was
extracted as above, and 300 ng of RNA was hybridised
onto modified Agilent 4 9 44K microarrays containing
201 additional probes, corresponding to 119 genes pre-
viously not found on the array (Agilent Technologies).
Raw data were extracted using Feature Extraction soft-
ware (Agilent Technologies) and analysed with ChipIn-
spector (Genomatix Software, Munich, Germany). Fold
change values were calculated for each gene in response
to IFN-a and IFN-c (mean signal value treatment/mean
signal value mock), as well as the ratio of responsiveness
to IFN-a versus IFN-c.
Results
Viral genotypes induce distinct liver transcriptomic
profiles
To explore viral genotype-specific changes in liver gene
expression, five of each of the gt1- and gt3-infected
specimens were selected for high-throughput sequence
analysis, on the basis of low fibrosis scores (METAVIR
fibrosis score ≤1) and RIN values >6.5 (Table S2).
From among the available uninfected biopsies, 4 sam-
ples were selected such that the control group included
conditions associated with liver disease as well as a nor-
(A) (B)
Fig. 1. Transcriptional profiles of liver biopsies from HCV gt1- and gt3-infected individuals compared with controls. (A) Significantly upregu-
lated and downregulated genes (ΔFPKM(log2) ≥1.0 and q-value <0.05) in gt1- and gt3-infected patients (each n = 5), versus controls
(n = 4). (B) Validation by Q-PCR (geometric mean with 95% confidence interval) in gt1-infected patients (n = 9, except CXCL9 and IDO1
n = 6), gt3-infected patients (n = 9) and controls (n = 6, except CXCL9 and IDO1 n = 4). * denotes P-value <0.05, ** denotes P-value
<0.01, and *** denotes P-value <0.001.
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mal liver sample (Table S2). This approach was
adopted to bias the resultant hits towards those regu-
lated exclusively by HCV rather than liver inflamma-
tion in general, although this possibly reduced the
number of hits that may have been obtained if solely
healthy liver samples were utilised as controls. RNA-
Seq generated ~17–25 million reads per sample, of
which 82–87% uniquely mapped to the human genome
(Table S2). All filtered sequence libraries had high
quality, with >90% of reads having a total mean Phred
quality score ≥32 and a mean per base Phred quality
score of >34 (Fig. 1).
We identified a total of 348 and 565 genes that were
differentially regulated (upregulated or downregulated
with ΔFPKM(log2) ≥1.0 and q-value <0.05 as detailed
in the supplementary data and summarised in Figure 1)
in the gt1- and gt3-infected samples, respectively, com-
pared to controls. A total of 196 genes were common to
both gene sets (56% of the total differentially regulated
genes in the gt1 samples and 35% of the total differen-
tially regulated genes in the gt3 samples).
To directly explore viral genotype-specific transcrip-
tional profiles, we analysed the sequencing data to
identify genes differentially regulated between the gt1-
and gt3-infected biopsies. A total of 149 genes were
differentially regulated between the gt1- and gt3-
infected samples with ΔFPKM(log2) ≥1.0 and q-value
<0.05 (64 upregulated in gt3, 85 upregulated in gt1;
Figure S2 and supplementary data). The finding that a
significant number of genes are differentially regulated
between the viral genotypes, together with the low
level of overlap between the transcriptional profiles
generated comparing either gt1- or gt3-infected sam-
ples to controls, highlights that viral genotype has a
large influence on the regulation of host genes during
chronic HCV infection.
To validate the RNA-Seq results, several differentially
regulated genes were examined by Q-PCR using all
available 24 liver RNA samples. The selected targets
included genes that were differentially expressed in both
gt1- and gt3-infected samples versus controls (CXCL9,
IFIT1, ISG15 and RSAD2), as well as genes that were dif-
ferentially regulated only in gt1 infection (USP18) or gt3
infection (IDO1). The Q-PCR data corresponded closely
to the sequencing read counts confirming the RNA-Seq
results (Fig. 1B).
Enriched canonical pathways differ between HCV gt1 and
gt3 infections
To explore potential biological processes underlying the
observed transcriptional changes, the differentially
regulated genes identified were analysed for pathway
enrichment. The top enriched canonical pathways in the
gt1- and gt3-infected liver biopsies compared to the
controls differed markedly, with only three shared path-
ways in the top 10 enriched pathways, paralleling the
small proportion of differentially regulated genes com-
mon to both comparisons (Table S3). While innate
immune pathways were evident in the gt1-infected liver
biopsies (e.g. activation of IRF by cytosolic pattern rec-
ognition receptors and interferon signalling), pathways
relating to adaptive immune responses were more
apparent in the gt3-infected liver biopsies (e.g. altered
T- and B-cell signalling in rheumatoid arthritis, cal-
cium-induced T-lymphocyte apoptosis, iCOS-iCOSL
signalling in T-helper cells, B-cell development and
CD28 signalling in T-helper cells). Despite the clinical
association of gt3 infection with increased prevalence of
liver steatosis and decreased peripheral cholesterol levels
(7), no enrichment of lipid or cholesterol metabolic
pathways occurred in the gt3-infected samples.
Pathway analysis was also performed on the 149
genes identified as differentially regulated between
gt1- and gt3-infected liver biopsies. Among the top
enriched canonical pathways, the antigen presentation
pathway had the highest enrichment in gt3-infected
samples, with B-cell development, allograft rejection
signalling and altered T- and B-cell signalling in
rheumatoid arthritis, also enriched in the gt3-infected
patients (Table 2). The differentially regulated genes
within these pathways include HLA genes involved in
presentation of antigen to T-helper cells (HLA-DQB2,
HLA-DRB1, HLA-DMA, HLA-DRA) as well as CD74,
also known as the HLA invariant chain, which acts
as a chaperone to regulate antigen presentation. Con-
versely, the interferon signalling pathway was
enriched in the gt1-infected liver biopsies (Table 2),
due to the elevated expression of a number of known
ISGs, such as OAS1, MX1 and IFIT1.
Type II IFN expression is elevated in HCV gt3 infection
The RNA-Seq data indicated that both gt1 and gt3
induced transcription of a number of ISGs within the
liver, and this ISG induction was particularly evident in
gt1 infection. To explore potential upstream regulators
of the ISG response, we profiled transcription levels of
Table 2. Top 5 canonical pathways between gt1- and gt3-infected
liver biopsies
Gt1 vs Gt3
P-value
(log) Ratio*
Up- or
Downregulated
in Gt1†
Antigen Presentation Pathway 5.48 0.135 Down
B-Cell Development 2.91 0.088 Down
Interferon Signalling 2.83 0.083 Up
Allograft Rejection Signalling 2.68 0.047 Down
Altered T-Cell and B-Cell
Signalling in Rheumatoid
Arthritis
2.64 0.046 Down
*Ratio of list genes found per pathway over the total number of genes
in that pathway.
†Based on the up- or downregulation of individual differentially regu-
lated genes belonging to the canonical pathway.
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type I, type II and type III IFNs, including IFNA2,
IFNB1, IFNL2 and IFNG.
We detected expression of IFNA2, IFNB1 and IFNL2
in fewer than half of the biopsy samples and could not
reliably quantify expression levels (data not shown).
This low level of type I and type III IFN expression was
also observed in the RNA-Seq data (data not shown),
indicating that elevated type I and type III IFN expres-
sion is unlikely to directly account for the transcrip-
tional changes observed in gt1-infected liver biopsies.
Likewise, the role of type I, type II and type III IFN
receptors could also be excluded as they were stably
expressed across all biological groups (data not shown).
Of the 4 tested IFN genes, only IFNG was expressed at a
level that allowed reliable detection in liver tissues.
IFNG expression was significantly higher in gt3-infected
patients but did not differ significantly in gt1 infection
compared to the control group (Fig. 2A). Several genes
identified within the gt3-specific enriched pathways are
induced by IFN-c, suggesting that the observed increase
in IFNG gene expression may contribute to upstream
regulation of these gt3-specific cellular pathways.
Identification of IFN-a- and IFN-c-regulated genes in
human hepatocyte-derived cell lines
As the transcriptional changes induced by different
types of IFN overlap significantly (19, 20), it is difficult
to classify ISGs as exclusively responsive to a particular
type of IFN. Many ISGs do however show a preferential
response to either type I or type II IFN. To identify par-
ticular ISGs which are preferentially induced by either
IFN-a or IFN-c in hepatocytes, we tested the effect of
stimulation by both IFNs on 2 hepatocyte-derived cell
lines, HuH-7 and HepaRG cells. By comparing the ratio
of the IFN-a/IFN-c fold change values in HuH-7 and
HepaRG cells 24 hours following stimulation, we identi-
fied 14 preferentially IFN-a-responsive genes and 74
preferentially IFN-c-responsive genes, 3 of which were
consistently downregulated by IFN-c (Table S4). Com-
paring the in vitro and in vivo results, the gt1-infected
liver biopsies had a greater upregulation of 9 of the 14
identified preferentially IFN-a-responsive genes, while
gt3-infected liver biopsies had a greater upregulation of
18 of the 22 identified preferentially IFN-c-responsive
(A)
(C)
(B) Fig. 2. Type II IFN transcription and downstream gene induction
are elevated in HCV gt3 infection. (A) IFNGmRNA levels (geometric
mean with 95% confidence interval) in gt1-infected patients
(n = 9), gt3-infected patients (n = 9) and controls (n = 6). **
denotes P-value <0.01. (B) Preferentially IFN-a- and IFN-c-respon-
sive genes identified in HuH-7 and HepaRG cells and upregulated in
liver biopsies from either gt1- (n = 5) or gt3-infected patients
(n = 5), versus controls (n = 4). (C) Fold change of preferentially
IFN-a- and IFN-c-regulated genes in gt1- and gt3-infected liver
biopsies versus control liver biopsies. The dotted line represents the
ΔFPKM(log2) ≥1.0 cut-off used to select differentially regulated
genes. * denotes q-value <0.05, and ** denotes q-value <0.01.
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genes (Fig. 2B and C). These results support a role for
IFN-c in driving gene transcription in the context of gt3
infection, while HCV gt1 infection is associated with a
type I IFN-like transcriptional signature.
The influence of IFNL4 polymorphisms on ISG expression
is evident in gt1 infection but not gt3 infection
Previous studies have linked polymorphisms
rs12979860 and rs8099917 located near IFNL3 to HCV
susceptibility (21) and response to IFN-a-based therapy
(22, 23). While the biological mechanisms underlying
this association are debated, elevated induction of ISGs
is observed in individuals carrying the unfavourable
polymorphisms (24). More recent genetic analysis has
revealed another polymorphism (rs368234815; previ-
ously designated ss469415590) in exon 1 of IFNL4,
which is in high linkage disequilibrium with rs12979860
and, indeed, is a better marker for HCV clearance in
certain ethnic populations (18). The expression of
Fig. 3. ISG mRNA transcription in gt3-infected liver biopsies is not influenced by IFNL4 genotype. Dot plots of Q-PCR data segregated by
IFNL4 (rs368234815) genotype (with geometric mean denoted by a horizontal line). Samples with the TT/TT genotype are plotted as circles,
while samples with the DG/TT or DG/DG are plotted as squares. Fold changes values are calculated relative to the mean of the control group.
For the control group, n = 3 for both the TT/TT and DG/TT or DG/DG genotypes (except for CXCL9 and IDO9 where n = 2 for both geno-
types). For the gt1-infected group, n = 2 for the TT/TT genotype and n = 6 for the DG/TT or DG/DG genotypes (except for CXCL9 and IDO9
where n = 1 and n = 5 respectively). For the gt3-infected group, n = 6 for the TT/TT genotype and n = 3 for the DG/TT or DG/DG geno-
types.
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IFNL4 in tissue culture cells upregulates a number of
ISGs. However, the rs368234815 TT variant results in a
frameshift which disrupts the expression of IFNL4.
To determine whether the observed differences in
gene expression were related to not only viral genotype
but also host genetic background, we performed IFNL4
genotyping (rs368234815) on all but one of the samples
used in our study (as detailed in Table 1). As shown in
Figure 3, the presence of the DG variant, which would
lead to expression of IFNL4, correlated with higher
expression levels of ISGs such as IFIT1, ISG15, RSAD2
and USP18, within the gt1-infected group. Due to the
low number of samples with TT/TT genotype, statistical
analysis could not be performed within the gt1-infected
group; however, our results parallel previous studies of
gt1-infected individuals (24). In stark contrast, the
expression of genes specifically induced in gt3-infected
biopsies, such as CXCL9, IDO1 and IFNG, was not sig-
nificantly different regardless of IFNL4 genotype
(Fig. 3).
Discussion
Using high-throughput transcriptome sequencing, we
identified distinct hepatic transcriptional profiles associ-
ated with different viral genotypes within HCV-infected
liver biopsies. Gt1 infection correlated with elevated
type I IFN-like ISG transcription, while gt3 infection
was associated with higher transcription of genes
involved in cell-mediated immune responses and IFN-c
signalling. While previous studies have documented the
induction of type I IFN-inducible ISGs and antiviral cel-
lular pathways during chronic HCV infection, our
results highlight that elevated ISG transcription is
dependent on viral genotype. Hence, in contrast to gt1,
gt3 infection is associated with the enrichment of path-
ways relating to adaptive immune responses and a
weaker induction of ISGs. Despite the clinical associa-
tion of gt3 infection with liver steatosis, we failed to
detect any transcriptional differences in lipid metabolic
pathways in these patients with early stages of liver dis-
ease. A recent metabolic study has identified a gt3-spe-
cific decrease in the serum levels of cholesterol
metabolites (25), suggesting that changes associated
with gt3 infection and steatosis may only be evident at a
post-transcriptional level.
The pathways identified as regulated by HCV in pre-
vious studies vary considerably. Such variability
undoubtedly emerges from differences in the physiolog-
ical state of liver samples at time of collection, the extent
of liver disease and distinct host genetic backgrounds.
We have tried to minimise such variability by excluding
liver samples with evidence of cirrhosis and using both
normal liver samples, as well as samples from uninfected
patients with conditions associated with hepatic disease,
as controls. This approach has the impact of lowering
the number of genes identified due to generic pathologi-
cal processes within the liver, enabling a greater likeli-
hood of determining host genes that are specifically
regulated by HCV. Consequently, we believe that the
resultant RNA-Seq data provide greater certainty that
the up- and downregulation of cellular genes is virus
mediated.
A central question arising from our study is why gt1
and gt3 mediate such different hepatic transcriptional
responses. While we observed a general induction of ISGs
by both genotypes compared to controls, the panel of
induced ISGs was not identical. Whereas there is persis-
tent induction of ISGs in gt1 infection, gt3 promotes dif-
ferential expression of a larger set of genes, including
factors stimulated by IFN-c. We did not observe altera-
tions in either type I or type III IFN transcription in the
infected or uninfected biopsies. However, IFN-c mRNA
was expressed at significantly higher levels in gt3 infection
and is associated with elevated expression of type II IFN-
regulated genes. Elevated expression of type I IFNs is
known to regulate responses to type II IFNs (26, 27), via
downregulation of the IFN-c receptor (28). These exag-
gerated type I IFN responses can drive immunopathology
and antagonise protective IFN-c responses during bacte-
rial infections (29). In the context of HCV infection, exag-
gerated type I IFN-like responses may subvert the
development of protective cell-mediated immune
responses and suppress the expression of antiviral media-
tors that are driven by IFN-c signalling (20). The reduced
expression of HLA genes in gt1 infection compared to gt3
potentially impacts on antigen presentation within the
liver and may lead to the development of defective cellular
immune responses during gt1 infection.
From the perspective of treatment, high levels of ISGs
are associated with poor response to therapy (15, 24,
30). Basal activation of the type I IFN signalling pathway
induces a state of refractoriness to further stimulation
(31), most likely through the action of ISGs that act as
negative regulators of IFN-a signalling, such as the
SOCS proteins and USP18 (32–34). Elevated ISG induc-
tion in the liver is associated with IFNL3 polymor-
phisms (24), although this association is not apparent
within peripheral blood (35). The apparent discrepancy
between peripheral blood and liver suggests that the
effect of IFN-k polymorphisms is strongest at the local
site of HCV infection within the liver. These findings
highlight that both viral and host factors influence ISG
induction and the relative influence varies between local
sites of infection and the periphery.
While the mechanisms underlying the relationship
between IFN-k polymorphism, liver ISG induction and
treatment non-response are still unclear, recent studies
have suggested that the unfavourable polymorphisms
are associated with increased IFN-k receptor 1 expres-
sion (36) and enhanced AU-rich element-mediated
decay of IFNL3 mRNA (37). No differences were
detected in the expression levels of any of the IFN-k
mRNAs, nor in the mRNA expression of the unique IF-
NLR1 receptor subunit in our samples. However, the
induction of ISGs in gt1-infected liver biopsies did
Liver International (2015)
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correlate with the presence of the DG allele in IFNL4. By
contrast, there was no evidence for a link between
IFNL4 genotype and changes in gene expression in gt3
infection. These data provide a rationale for the reduced
efficacy of IFNL SNPs in predicting gt3 treatment out-
comes (38).
Our data demonstrate that gt1 infection drives a
highly skewed type I IFN-like response, which is appar-
ently influenced by host IFNL4 genotype. Conversely,
gt3 induces upregulation of IFN-c and IFN-c-respon-
sive ISGs, independent of host IFNL4 genotype. These
transcriptional differences highlight fundamental differ-
ences in host–pathogen interactions that exist between
different HCV genotypes and provide a platform for
further research into the impact of viral genotype on
host responses. Future studies that focus on changes in
liver gene expression elicited by other genotypes will be
important to understand how the natural history of
infection is influenced by viral variation. Such knowl-
edge will undoubtedly be vital to develop strategies for
predicting outcomes of therapy and combating the dif-
ferent HCV genotypes circulating within human popu-
lations.
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